Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement

Haematologica

Volumn 92, Issue 6, 2007, Pages 863-864

  Barrans, Sharon L ^a   Fenton, James A L ^a   Ventura, Roland ^b   Smith, Alex ^c   Banham, Alison H ^b   Jack, Andrew S ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOXP1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; PROTEIN EXPRESSION; REGULATORY MECHANISM; GENE EXPRESSION REGULATION; GENETICS; LETTER;

FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; REPRESSOR PROTEINS;

EID: 34347223285     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10656     Document Type: Article

References (10)

1. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004;104:2933-5.
2. Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005;11:1065-72.
3. Fenton JA, Schuuring E, Barrans SL, Banham AH, Rollinson SJ, Morgan GJ, et al. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2006;45:164-8.
4. Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, et al. Forkhead Box Protein P1 Expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell Lymphoma. J Clin Oncol 2006;24:2490-7.
5. Palanisamy N, Abou-Elella AA, Chaganti SR, Houldsworth J, Offit K, Louie DC, et al. Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes Cancer 2002;33:114-22.
6. Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005;19:1299-305.
7. Haralambieva E, Adam P, Ventura R, Katzenberger T, Kalla J, Höller S, et al. Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 2006;20:1300-3.
8. Streubel B, Vinatzer U, Lamprecht A, Raderer M & Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005;19:652-8.
9. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-6.
10. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. Lymphoma/leukemia molecular Profiling Project. The use of molecular profiling to predict survival after the chemotherapy for diffuse large B cell lymphoma. N Engl J Med 2002;346:1937-47.